AIM movers: Beowulf Kallak project challenge, Renalytix trial success and Camellia’s value

Beowulf Mining (LON: BEM) has been hit by attempts to stop the exploitation of the Gallok / Kallak iron ore project in Northern Sweden. The share price fell from 5.5p to 4.75p, having risen to 15.25p on the day that the Swedish government approval for the project was announced. A nearby Sami village is challenging the Swedish government’s decision to award the exploitation concession. They are concerned about how this will affect reindeer herding and Sami culture. The mine is in the middle of a traditional winter grazing area. The Sami village is holding a press conference on 15 June. Kallak has a measured and indicated mineral resource of 132Mt grading 27.8% Fe, 7.5% FeO, 48.9% SiO2, 4.4% AI2O3, 0.03% P and 0.002% S.

Kidney disease diagnostics company Renalytix (LON: RENX) has been boosted by positive news this week. A study of 1,112 patients with adult diabetic kidney disease has demonstrated clinical utility and care benefits of KidneyIntelX risk stratification in stages one to three of kidney disease. This means that doctors can assess which patients are at high-risk for loss of kidney function. Earlier this week, another study showed that KidneyIntelX can assess risk of heart failure and death in chronic kidney disease patients. The share price has risen 7p to 190p on the day, having started the week at 150p. Even so, the share price is less than one-fifth of its peak in 2021.

- Advertisement -

Technology focused recruitment and professional services provider Parity (LON: PTY) continues to gain momentum following its AGM statement on Wednesday. The share price has risen from 7.75p to 9p today having been 7p prior to the AGM. Parity has added four new clients in the private sector and been appointed for four local government frameworks. Parity was loss-making last year, but management believes that the performance will improve. Allenby was appointed as broker in May but does not appear to have published any forecasts yet. Previous broker finnCap did not have a 2022 forecast and it was targeting September for relaunching its forecasts. This indicates that it is difficult to assess whether the apparent optimism of investors is warranted.

Agricultural products supplier Camellia (LON: CAM) issued its annual report at the beginning of the week and the share price has risen from £60 to £66.25. This could have something to do with the fact that Camellia has a market capitalisation of £179.5m compared with net assets of £388.6m at the end of 2021. That includes £225m of property and equipment, including £23.1m of investment properties, plus net cash of £54m. Investors can still receive the final dividend of 102p a share until 7 July when the shares go ex-dividend.

- Advertisement -

Latest News

Subscribe to the UK Investor Magazine email newsletter

Register for our free email newsletter and receive the latest investment news, podcasts, event information and offers.

More Articles Like This

Tagdiv Cloud library - template content.